Literature DB >> 28775400

A STUDY ON TREATMENT OF CHRONIC IDIOPATHIC URTICARIA WITH CETIRIZINE.

P K Kar1, Kvr Chari2.   

Abstract

In a prospective study a comparison has been made between the clinical efficacy and safety of cetirizine, a third generation H1 receptor antagonist with chlorpheniramine and cyprohepatadine, the most widely used antithistamines in the treatment of chronic idiopathic urticaria. One hundred and five patients with chronic idiopathic urticaria were studied where the effects of chlorpheniramine, 4 mg and cyproheptadine, 4 mg administered twice daily were compared with cetirizine, 10 mg given once daily for 4 weeks or earlier till the relief of symptoms and regression of lesions. Local therapy consisted of calamine lotion in all cases. Out of 35 patients receiving chlorpheniramine excellent response was achieved in 9 (25.7%) cases by subjective evaluation (SE) and 11 (31.4%) by objective evaluation (OE). Out of 35 cases, 7 (20%) and 10 (28.5%) cases treated with cyproheptadine have shown excellent response by SE and OE respectively. Out of 35 patients taking cetirizine 25 (71.4%) had shown excellent response by SE and 22 (62.8%) cases by OE. Drowsiness was an important side effect observed in 19 (54.2%) cases receiving chlorpheniramine, 22 (62.8%) patients taking cyproheptadine and 1 (2.8%) case getting cetirizine. These results suggest that cetirizine has got superior antiallergic activity than chlorpheniramine and cyproheptadine in the treatment of chronic idiopathic urticaria.

Entities:  

Keywords:  Cetirizine; Urticaria

Year:  2017        PMID: 28775400      PMCID: PMC5531150          DOI: 10.1016/S0377-1237(17)30395-7

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN: 0377-1237


  13 in total

1.  Comparison of cetirizine and terfenadine in the treatment of chronic idiopathic urticaria.

Authors:  H Kietzmann; E Macher; J P Rihoux; L Ghys
Journal:  Ann Allergy       Date:  1990-12

Review 2.  The new H1 antihistamines. Treatment of urticaria and other clinical problems.

Authors:  P Goldsmith; P M Dowd
Journal:  Dermatol Clin       Date:  1993-01       Impact factor: 3.478

3.  Direct measurement of daytime sleepiness after administration of cetirizine and hydroxyzine with a standardized electroencephalographic assessment.

Authors:  W F Seidel; S Cohen; N G Bliwise; W C Dement
Journal:  J Allergy Clin Immunol       Date:  1990-12       Impact factor: 10.793

4.  A comparison of the efficacy of cetirizine and terfenadine. A double-blind, controlled study of chronic idiopathic urticaria.

Authors:  L Andri; G E Senna; C Betteli; S Givanni; G Andri; C Lombardi; P Mezzelani
Journal:  Allergy       Date:  1993-07       Impact factor: 13.146

Review 5.  Urticaria: current therapy.

Authors:  N A Soter
Journal:  J Allergy Clin Immunol       Date:  1990-12       Impact factor: 10.793

Review 6.  Recent advances in H1-receptor antagonist treatment.

Authors:  F E Simons
Journal:  J Allergy Clin Immunol       Date:  1990-12       Impact factor: 10.793

7.  Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo.

Authors:  J Kalivas; D Breneman; M Tharp; S Bruce; M Bigby
Journal:  J Allergy Clin Immunol       Date:  1990-12       Impact factor: 10.793

Review 8.  The pharmacology and use of H1-receptor-antagonist drugs.

Authors:  F E Simons; K J Simons
Journal:  N Engl J Med       Date:  1994-06-09       Impact factor: 91.245

9.  Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial.

Authors:  D Breneman; E A Bronsky; S Bruce; J T Kalivas; G L Klein; H L Roth; M D Tharp; C Treger; N Soter
Journal:  J Am Acad Dermatol       Date:  1995-08       Impact factor: 11.527

10.  Effect of cetirizine on cutaneous reactions to PAF, kallikrein and serum in patients with chronic urticaria.

Authors:  L Juhlin; J P Rihoux
Journal:  Acta Derm Venereol       Date:  1990       Impact factor: 4.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.